前淋巴细胞白血病:关于生物学和治疗的最新情况
Dima El-Sharkawi1,2, Claire Dearden3,4
1Royal Marsden NHS Foundation Trust, London, UK. dima.el-sharkawi@rmh.nhs.uk.
Current oncology reports
|January 12, 2024
概括
在前淋巴细胞性白血病 (PLL) 中最近的进展揭示了B细胞和T细胞类型的复杂遗传. 虽然B-PLL治疗有希望,但T细胞前淋巴细胞白血病 (T-PLL) 缺乏治疗进展.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 前淋巴细胞性白血病 (PLL),包括B细胞 (B-PLL) 和T细胞 (T-PLL) 亚型,具有显著的遗传复杂性.
- 最近的研究已经阐明了这些血液性恶性瘤的分子格局.
研究的目的:
- 总结了解B-PLL和T-PLL的生物学和治疗方面的最新进展.
- 突出目前在管理这些罕见白血病方面的挑战和未满足的需求.
主要方法:
- 对B-PLL和T-PLL的遗传学,诊断和治疗方法的当前文献的综述.
- 分析最近的诊断标准,更新和治疗策略.
主要成果:
- B-PLL和T-PLL的分子基础已经得到了显著的特征.
- 对T-PLL的诊断标准已经得到了改进,而B-PLL的分类正在修订中.
- 治疗B-PLL受益于慢性淋巴细胞白血病 (CLL) 的治疗进展,尽管证据有限.
- 尽管有生物学见解,但T-PLL治疗仍然具有挑战性,没有显著的治疗改善.
结论:
- 前淋巴细胞性白血病在B细胞和T细胞亚型的诊断和治疗中存在明显的挑战.
- 对于有效的疗法,特别是T-PLL,存在着至关重要的未满足的需求.
- 对PLL生物学的进一步研究对于开发未来治疗方法至关重要.
更多相关视频
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
21.2K
08:00A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016
20.2K
相关概念视频
Disorders of Leukocytes
956
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
956
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Bone Marrow Sampling and Transplants
332
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
332
Lineage Commitment
3.0K
Commitment is the process whereby stem cells:
3.0K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
